Kymera CMO sells 3,114 shares at $60; exercises options

Kymera Therapeutics (KYMR): insider transaction — The company’s Chief Medical Officer reported multiple trades on 10/13/2025.

Rhea-AI Filing Summary

Kymera Therapeutics (KYMR): insider transaction — The company’s Chief Medical Officer reported multiple trades on 10/13/2025. The officer exercised stock options for 800 shares at $1.31 and 673 shares at $2.08, then sold 3,114 shares at $60. Following these transactions, the officer directly owned 118,359 shares of common stock. The filing notes these trades were made under a Rule 10b5-1 trading plan dated June 2, 2025. The exercised options were fully vested and remain tied to grants expiring on 10/31/2028 and 05/22/2029.

Insights

Equity markets analyst

Planned insider trades; routine liquidity and option exercise.

The CMO exercised vested options at strike prices of $1.31 and $2.08 and sold 3,114 shares at $60. Such sequences are typical when insiders convert options and manage holdings.

The transactions were executed under a Rule 10b5-1 plan dated June 2, 2025, which pre-schedules trades to reduce discretion. Post-trade direct ownership is 118,359 shares.

Actual market impact depends on trade size relative to average volume and float; the excerpt does not provide that context. Subsequent filings may provide additional detail on future plan-driven sales.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Gollob Jared

Role Chief Medical Officer

Sold 3,114 shs ($187K)

Approx. gross sale proceeds $187K

Approx. exercise cost $2K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	800	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	673	$0.00	$0.00
Exercise	Common Stock	800	$1.31	$1K
Exercise	Common Stock	673	$2.08	$1K
Sale	Common Stock	3,114	$60.00	$187K

Holdings After Transaction: Stock Option (Right to Buy) — 51,209 contracts (Direct); Common Stock — 118,359 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.
2. F2. The shares underlying this stock option are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did KYMR’s CMO report in the latest Form 4?

Exercises of options for 800 shares at $1.31 and 673 shares at $2.08, and a sale of 3,114 shares at $60 on 10/13/2025.

How many KYMR shares does the insider own after the transactions?

Direct ownership is 118,359 shares following the reported trades.

Were the KYMR insider trades under a 10b5-1 plan?

Yes. The filing states trades were effected under a Rule 10b5-1 plan dated June 2, 2025.

What were the strike prices of the exercised KYMR options?

$1.31 and $2.08 per share.

What are the expirations of the exercised KYMR option grants?

The grants list expirations on 10/31/2028 and 05/22/2029.

What was the sale price for the KYMR shares sold?

The reported sale price was $60 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Gollob Jared

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/13/2025		M(1)		800	A	$1.31	120,800	D
Common Stock	10/13/2025		M(1)		673	A	$2.08	121,473	D
Common Stock	10/13/2025		S(1)		3,114	D	$60	118,359	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.31	10/13/2025		M(1)			800	(2)	10/31/2028	Common Stock	800	$0	28,999	D
Stock Option (Right to Buy)	$2.08	10/13/2025		M(1)			673	(2)	05/22/2029	Common Stock	673	$0	22,210	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person.

2. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.